Jennifer A. Woyach, MD, Discusses Exciting Abstracts at ASH 2021

During the 2021 American Society of Hematology Annual Meeting, Jennifer A. Woyach, MD, associate professor in the Division of Hematology at The Ohio State University, discussed abstracts she’s most looking forward to seeing presented.

Transcript:

There are going to be a lot of exciting data coming out at ASH this year. From a clinical standpoint, I’m interested in the longer-term follow-up of some studies that have been previously presented. In terms of frontline and relapse therapy, there is a lot of exciting studies comparing ibrutinib [Imbruvica] or other Bruton tyrosine kinase [BTK] inhibitors plus venetoclax [Venclexta]. We’re going to see follow-up from some of those studies at this meeting, which I’m excited to see because those combinations have shown excellent efficacy, but follow-up has been extremely short for most of the studies.

We’re also seeing follow-up from some of the reversible BTK inhibitors [such as] pirtobrutinib [LOXO-305] as well as nemtabrutinib [MK-1026]. Those are drugs that are intended to be given after patients become resistant to covalent BTK inhibitors like ibrutinib and acalabrutinib [Calquence]. I’m excited to see the follow-up of their studies as well.